Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HAILEY 1.5/30 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol and desogestrel. Ethinyl estradiol suppresses gonadotropin release via negative feedback on the hypothalamic-pituitary axis; desogestrel, a progestin, inhibits ovulation and alters cervical mucus and endometrial receptivity.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy
Prevention of pregnancy (FDA-approved)
One tablet (ethinyl estradiol 0.03 mg, levonorgestrel 0.15 mg) orally once daily at the same time each day for 21 days, followed by 7 placebo tablets. For continuous cycling, may take active tablets daily without placebo.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal elimination half-life of ethinyl estradiol is 13-27 hours (mean 17 hours); for norgestimate, active metabolite norelgestromin has half-life 12-30 hours (mean 19 hours). Steady state reached after 7-14 days.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol undergoes hepatic metabolism primarily via CYP3A4; desogestrel is rapidly metabolized to its active metabolite etonogestrel via hydroxylation and dehydrogenation, further metabolized via CYP2C9 and CYP3A4.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Approximately 40% renal (as metabolites), 32% fecal (as metabolites), and <1% unchanged in urine.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Ethinyl estradiol: ~98% bound to albumin; norelgestromin: ~99% bound to albumin and SHBG.
~99% bound to serum albumin and sex hormone-binding globulin.
Ethinyl estradiol: 2.3-4.0 L/kg; norelgestromin: 2.0-3.5 L/kg. Indicates extensive tissue distribution.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: Ethinyl estradiol 40-55% (first-pass metabolism); norelgestromin: ~80% (as metabolite of norgestimate).
Oral: ~70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe impairment, but estrogen metabolites may accumulate; use caution.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in acute liver disease or severe hepatic impairment (Child-Pugh C). For mild to moderate (Child-Pugh A or B), use is not recommended due to altered hormone clearance; if used, monitor liver function and consider lower estrogen dose.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Postmenarchal adolescents: Same adult dosing (one tablet daily). Safety and efficacy not established in premenarchal girls.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for postmenopausal women; contraindicated after menopause due to increased risk of cardiovascular events. No specific geriatric dose.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases the risk of serious cardiovascular side effects from combination oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders,Cigarette smoking increases cardiovascular risk,Elevated blood pressure,Gallbladder disease,Hepatic neoplasia,Carbohydrate and lipid effects,Ocular lesions,Headache/migraine,Bleeding irregularities,Depression
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Active or history of venous thromboembolism,Cerebrovascular disease,Coronary artery disease,Valvular heart disease with complications,Thrombogenic valvulopathies,Major surgery with prolonged immobilization,Diabetes with vascular involvement,Uncontrolled hypertension,Active liver disease,Known or suspected pregnancy,Breast cancer or other estrogen-sensitive neoplasia,Heavy smoking (≥15 cigarettes/day) and age ≥35
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but not clinically relevant. A high-fat meal may delay absorption but does not reduce efficacy. Avoid excessive alcohol as it may increase liver enzymes and theoretically reduce efficacy.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
FDA Pregnancy Category X. Combined hormonal contraceptives (CHCs) are contraindicated in pregnancy. First trimester exposure is associated with a low risk of fetal malformations; however, CHCs should be discontinued if pregnancy occurs. Second and third trimester exposure may increase risks of fetal adverse outcomes, including but not limited to congenital anomalies and fetal demise. Use is not recommended at any trimester.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
CHCs may reduce milk production and composition. Small amounts of synthetic estrogen and progestin are excreted in breast milk. M/P ratio not specifically reported for this combination; ethinyl estradiol M/P ratio approximately 0.02-0.05. Use during lactation is generally not recommended, especially in early postpartum period. Alternative contraception should be considered.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Contraindicated in pregnancy; no dose adjustments applicable as drug should be discontinued immediately upon confirmed pregnancy. Pharmacokinetic changes during pregnancy (e.g., increased clearance) are not relevant given contraindication.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
HAILEY 1.5/30 is a combination oral contraceptive containing ethinyl estradiol 30 mcg and levonorgestrel 1.5 mg. It is a monophasic pill with 21 active tablets. Counsel patients that missed pills increase pregnancy risk, especially if more than one active pill is missed. Use back-up contraception for 7 days if a dose is missed. Consider increased risk of venous thromboembolism (VTE) in smokers over 35, obese patients, or those with thrombophilia. Nausea may be reduced by taking with food or at bedtime. Spotting is common in first 3 cycles; if persistent, rule out pregnancy or other causes.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill daily at the same time for 21 days, then 7 placebo pills.,If you miss a pill, follow the package insert instructions for missed doses and use back-up contraception (e.g., condoms) for 7 days.,Do not smoke while taking this medication, especially if over age 35, due to increased risk of blood clots.,Common side effects include nausea, breast tenderness, and spotting, which usually improve after 3 cycles.,Seek immediate medical attention for symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, or severe headache.,Antibiotics (except rifampin) do not reduce effectiveness; however, certain drugs like rifampin, griseofulvin, and some anticonvulsants may decrease efficacy.,Store at room temperature, away from moisture and heat.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HAILEY 1.5/30 vs AFIRMELLE, answered by our medical review team.
HAILEY 1.5/30 is a Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and desogestrel. Ethinyl estradiol suppresses gonadotropin release via negative feedback on the hypothalamic-pituitary axis; desogestrel, a progestin, inhibits ovulation and alters cervical mucus and endometrial receptivity.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HAILEY 1.5/30 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HAILEY 1.5/30 is: One tablet (ethinyl estradiol 0.03 mg, levonorgestrel 0.15 mg) orally once daily at the same time each day for 21 days, followed by 7 placebo tablets. For continuous cycling, may take active tablets daily without placebo.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HAILEY 1.5/30 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HAILEY 1.5/30 is classified as Category C. FDA Pregnancy Category X. Combined hormonal contraceptives (CHCs) are contraindicated in pregnancy. First trimester exposure is associated with a low risk of fetal malformations; h. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.